Mastalgia (breast pain) — the Australian general practice guide

Mastalgia — pain perceived to arise from breast tissue — is among the most common reasons Australian women present to their GP. Around 70% of women experience it at some point, and roughly 10% have moderate-to-severe pain that affects sleep, work, or sexual activity. Despite its frequency, mastalgia causes substantial anxiety because many women fear it signals breast cancer.

The GP’s role is dual: first, exclude malignancy through structured assessment; second, manage the pain. Both tasks matter. Dismissing breast pain without examination is medico-legal risk. Over-investigating typical cyclical pain in a young woman with no risk factors is unnecessary and adds anxiety. The skill lies in calibrating the workup to clinical probability.

A. Core clinical — the AU general-practice framework

Classification

There are three clinical subtypes, each with a different cause and management path.

Cyclical mastalgia (60–70%): pain that tracks the menstrual cycle, building in the luteal phase (days 14–28), peaking premenstrually, and relieving with menstruation. It is typically bilateral, diffuse, and felt as heaviness or aching in the upper-outer quadrant. Peak age is the 30s to 40s. It is worsened by combined oestrogen-progestogen oral contraceptives, menopausal hormone therapy, and fertility stimulation, and suppressed by anovulation, pregnancy, and menopause.

Non-cyclical mastalgia (30–40%): no menstrual relationship; often focal, unilateral, and described as sharp or burning. Causes include cysts (acute distension or rupture), ductal ectasia (peri- or post-menopausal), trauma or fat necrosis, peri-ductal mastitis (associated with smoking), post-surgical scar pain, and large-breast ergonomic load on Cooper’s ligaments.

Extra-mammary pain (approximately 10%): chest-wall pain misattributed to the breast. Key causes are costochondritis (tender at costochondral junctions — Haagensen pinch test separates breast from chest-wall tenderness), thoracic or cervical radiculopathy, GORD-referred burning, pre-eruptive herpes zoster, shoulder or acromioclavicular joint pathology, and — rarely but critically — atypical cardiac ischaemia in women with cardiovascular risk factors.

History

The single most useful diagnostic tool is a two-to-three cycle pain diary using a visual analogue scale. This reliably distinguishes cyclical from non-cyclical patterns and provides a baseline for judging response to treatment. The RACGP 2017 AFP article describes the Cardiff Breast Pain Chart for this purpose.

Key history elements:

• Pattern: does pain rise and fall with the menstrual cycle?
• Location (clock-face quadrant), quality (heaviness, sharp, burning), radiation (axilla, arm)
• Associated features: lump, nipple discharge (colour, spontaneous vs expressed, single vs multiple ducts), skin change, nipple change
• Drug history: combined OCP, menopausal hormone therapy, fertility treatment, antipsychotics (hyperprolactinaemia), SSRIs
• Smoking (peri-ductal mastitis link)
• Reproductive status: LMP, parity, breastfeeding, menopausal status
• Family history of breast cancer (three-generation pedigree), prior breast biopsy, previous chest radiotherapy before age 30 (Hodgkin lymphoma survivors), genetic mutations (BRCA1/2, PALB2)

Examination

Every woman presenting with breast pain requires bilateral breast and axillary examination, regardless of how typical the presentation sounds. The examination technique:

• Position: upright with arms relaxed, then raised, then hands on hips
• Inspect: symmetry, skin texture, peau d’orange, dimpling, nipple position, eczematoid nipple change
• Palpate both breasts systematically using the flat-hand vertical-strip technique; document any mass by size, clock-face position, distance from areola, consistency, and mobility
• Axillary, supraclavicular, and infraclavicular nodes
• Chest-wall test: ask the patient to lean forward — reproducible tenderness that moves with the chest wall rather than the breast suggests costochondritis

Investigations — risk-stratified imaging

Not all mastalgia requires imaging. Per Cancer Australia:

• No imaging needed: typical bilateral cyclical pain, normal examination, age under 35, no risk factors. Reassurance and pain diary.
• Age ≥35 with focal, persistent, or non-cyclical pain, or any clinical concern: bilateral diagnostic mammography plus targeted ultrasound of the symptomatic area.
• Age under 35 with focal or persistent pain, or any clinical concern: targeted ultrasound first-line (dense glandular tissue limits mammography sensitivity at this age); add mammography if ultrasound is equivocal or clinical concern is high.
• Triple test for any persistent focal lesion identified on imaging: clinical examination + imaging + fine-needle aspiration or core biopsy (performed by the breast surgical team).

Do not use BreastScreen Australia for symptomatic women. It is a free population-screening programme for asymptomatic women aged 50–74 and is not appropriate for investigation of a new symptom.

Selective blood tests: TSH if galactorrhoea or hypothyroid features; serum prolactin if galactorrhoea, amenorrhoea, or suspected pituitary cause; beta-hCG in any woman who could be pregnant before mammography or before starting tamoxifen.

B. Guideline-aligned management

Step 1 — Reassurance after structured assessment

RACGP 2017 reports that reassurance alone — after focused history, examination, and appropriate imaging — resolves moderate-to-severe cyclical mastalgia in approximately 70% of women within three to six months. Explaining that typical cyclical pain is a hormonal variation, not a cancer signal, and providing a written safety-net plan (return if new lump, discharge, skin change, or persistent focal pain) constitutes effective management for the majority.

Step 2 — Physical and lifestyle measures

Properly fitted sports bra: the strongest non-pharmacological evidence. Mason’s 1999 randomised trial showed significant pain reduction when a professionally fitted sports bra was worn continuously through the symptomatic phase, including at night. Referral to a professional bra-fitting service is a practical step; community bra-bank services exist in most metropolitan areas.

A two-to-three cycle pain diary helps confirm pattern and track treatment response.

Modest supporting evidence for caffeine reduction (a four-to-eight week trial is reasonable in motivated patients; not mandatory) and weight optimisation for BMI above 25 (reduces adipose oestrogen production).

Step 3 — Topical and oral analgesia

Per eTG and NICE CKS:

• Topical diclofenac 1% gel applied to the symptomatic area three to four times daily — preferred first-line analgesic. A 2003 randomised controlled trial showed it was superior to oral diclofenac at six months for both cyclical and non-cyclical mastalgia, with fewer gastrointestinal adverse effects. Available over the counter in Australia.
• Paracetamol 1 g four times daily regular dosing — adjunct; less evidence than topical NSAID.
• Short-course oral ibuprofen 400 mg three times daily as needed — appropriate if topical insufficient.

Avoid applying topical agents directly to the nipple or areola.

Step 4 — Review hormonal medications

If a combined oral contraceptive or combined menopausal hormone therapy is contributing, a trial of formulation change is reasonable before pharmacotherapy: switch to a progestogen-only contraceptive, lower-dose combined pill, or transdermal oestrogen alone with intermittent progestogen. Review fertility medications with the managing fertility specialist.

Step 5 — Second-line pharmacotherapy for severe refractory cyclical mastalgia

Reserved for women with severe cyclical mastalgia persisting despite six months of Steps 1–4, and preferably initiated with breast clinic support. Per eTG:

Tamoxifen 10 mg daily for three to six months (off-label for mastalgia; PBS-listed for breast cancer treatment) — approximately 80% response rate. Counsel on: endometrial cancer risk (relative risk 2–3; small absolute risk over a short course), venous thromboembolism risk (relative risk approximately 2), hot flushes, and teratogenicity. Effective contraception is mandatory. A negative pregnancy test must be confirmed before starting. A beta-hCG result before mammography and before tamoxifen initiation is a safety-critical step that is commonly omitted.

Continuous progestogen-only contraception (depot medroxyprogesterone, levonorgestrel-IUD, progestogen-only pill) suppresses ovulation and often improves cyclical mastalgia — a reasonable alternative to tamoxifen with fewer systemic risks.

Danazol, bromocriptine, and goserelin are now rarely used given their side-effect profiles; refer to a specialist before initiating.

C. Differential diagnosis — must not dismiss

Diagnosis	Distinguishing features
Breast cancer	Focal, persistent, unilateral pain; ± lump, discharge, or skin change; postmenopausal new pain
Fibrocystic change	Cyclical lumpiness with bilateral diffuse tenderness
Simple cyst	Focal acute pain from rapid enlargement or rupture; ultrasound confirms
Lactational mastitis	Breastfeeding; firm, erythematous, localised; fever
Peri-ductal mastitis	Smoker; sub-areolar pain ± fistula
Ductal ectasia	Peri- or postmenopausal; sub-areolar burning, thick discharge
Costochondritis	Reproducible chest-wall tenderness at costochondral junction; Haagensen pinch test
GORD	Burning retrosternal radiation; trial proton pump inhibitor
Pre-eruptive herpes zoster	Dermatomal; rash within days
Cardiac ischaemia	Exertional; cardiovascular risk factors; urgently assess
Inflammatory breast cancer	Peau d’orange, rapid onset, erythema; emergency referral

D. Australian operations

MBS items:

• Standard consultations: Level B (item 23), Level C (item 36, appropriate for full mastalgia assessment including diary review), Level D (item 44, for complex hereditary-risk discussion)
• Telehealth: video (item 91790) and phone (items 92029/92060) for diary review and reassurance follow-up in established patients
• Diagnostic mammography — bilateral (item 59300), unilateral (item 59303) — diagnostic indication required; not for asymptomatic screening
• Breast ultrasound — single breast (item 55070), bilateral (item 55076)
• Mental Health Treatment Plan (items 2715/2717) for women with significant cancer anxiety or chronic-pain distress; psychology via Better Access (items 80000–80020)
• ATSI Health Assessment (item 715) — includes breast-awareness counselling

PBS:

• Paracetamol and ibuprofen: PBS general schedule and over the counter
• Topical diclofenac 1% gel: over the counter (approximately AUD 10–20; not PBS-subsidised for this indication)
• Tamoxifen: PBS Authority Required for breast cancer treatment and high-risk risk reduction — private prescription for mastalgia indication (approximately AUD 20–40 per month)

Referral guide:

Scenario	Destination	Urgency
Discrete lump on examination	Breast surgical clinic	Two weeks
Bloody or single-duct nipple discharge	Breast surgical clinic	Two weeks
Skin change or nipple eczema	Breast surgical clinic	Two weeks
Postmenopausal new focal unilateral pain	Breast clinic + diagnostic imaging	Two weeks
Persistent focal unilateral pain >3 months	Breast surgical clinic	Soon
Severe refractory cyclical mastalgia for tamoxifen	Breast surgical clinic	Soon
Significant cancer anxiety	Psychology via MHTP	Routine
Suspected hereditary cancer (strong family history, BRCA mutation)	Family Cancer Clinic	Routine

E. Special populations

Postmenopausal women. New focal unilateral breast pain in a postmenopausal woman is a red flag requiring imaging regardless of the history. Ductal ectasia is common at this age (sub-areolar burning, thick discharge). Inflammatory breast cancer is rare but presents as peau d’orange with rapid progression and must not be misdiagnosed as mastitis.

Trans women on feminising hormones. Oestradiol-based feminising hormone therapy can cause mastalgia as breast development occurs — this is expected and generally managed with the same supportive measures (properly fitted bra, paracetamol, topical analgesia). A new discrete lump or other red flag still requires evaluation.

Lactating women. Breast pain during breastfeeding has a distinct differential — nipple trauma, incorrect latch, engorgement, blocked duct, or mastitis. See the specific lactation-mastitis resource for this population.

Women with BRCA1/2 or strong family history. All the management principles apply, but a lower threshold for imaging applies at any age given elevated baseline cancer risk. Refer to a Family Cancer Clinic for genetic counselling if not already engaged.

When to escalate

Refer urgently to a breast surgical clinic when any of the following are found at any point in the assessment:

• A discrete palpable lump
• Spontaneous nipple discharge, especially blood-stained or from a single duct
• Skin changes: peau d’orange, dimpling, erythema, or nipple retraction
• Nipple eczema — Paget’s disease must be excluded by biopsy
• Postmenopausal new focal unilateral pain
• Persistent unilateral focal pain exceeding three months despite structured management

Refer semi-urgently for severe refractory cyclical mastalgia warranting tamoxifen initiation, significant cancer anxiety requiring psychological support, or suspected hereditary cancer syndrome.

What this article is and is not

This is general health information drawn from current Australian guidelines — RACGP 2017, Therapeutic Guidelines, Cancer Australia, BreastSurgANZ, and NICE CKS. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about imaging, medication, and referral are made in the context of the individual clinical picture with the treating GP and specialist team.

For Australian consumer resources: HealthDirect — Breast pain, Jean Hailes for Women’s Health, Breast Cancer Network Australia. Cancer Council: 13 11 20.

---

Sources cited

1. RACGP — Mastalgia: assessment and management (AFP 2017)
2. Therapeutic Guidelines — Mastalgia
3. Cancer Australia — Investigation of a new breast symptom
4. BreastSurgANZ position statements
5. RANZCOG — Breast pain statement
6. BreastScreen Australia Program
7. NICE CKS — Breast pain
8. Cochrane — Treatments for breast pain (Srivastava 2007)
9. Mason — Sports bra RCT (Br J Sports Med 1999)
10. Colak — Topical diclofenac RCT (J Am Coll Surg 2003)
11. HealthDirect — Breast pain
12. Jean Hailes for Women’s Health
13. Breast Cancer Network Australia